Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum WPD Pharmaceuticals Inc WPDPF


Primary Symbol: C.WBIO

WPD Pharmaceuticals Inc. is a Canada-based clinical-stage pharmaceutical company, with a focus on glioblastoma cancer (GBM) and other brain tumor programs. The Company is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. It has four novel drug candidates with one in... see more

CSE:WBIO - Post Discussion

WPD Pharmaceuticals Inc > Worldwide Clinical Trials as CRO for Phase 2 Berubicin Trial
View:
Post by etcetera on Sep 09, 2020 7:51am

Worldwide Clinical Trials as CRO for Phase 2 Berubicin Trial

VANCOUVER, British Columbia, Sept. 09, 2020 (GLOBE NEWSWIRE) --

WPD Pharmaceuticals Inc. (“WPD” or the “Company”) (CSE: WBIO) (FSE: 8SV1),

a clinical stage pharmaceutical company, is pleased to announce that is has engaged world-renowned Contract Research Organization (“CRO”),

Worldwide Clinical Trials (“WCT”) to coordinate and supervise Phase 1 and 2 clinical trials on its Berubicin drug candidate.

Berubicin is a new drug and one of the first anthracyclines proven to cross the blood-brain barrier to reach brain tumors.

The discovery and further development of Berubicin can potentially extend the clinical use of anthracyclines to brain tumors,

specifically Glioblastoma, an aggressive type of cancer that can occur in the brain or spinal cord .


https://www.globenewswire.com/news-release/2020/09/09/2090784/0/en/WPD-Pharmaceuticals-Engages-Worldwide-Clinical-Trials-as-CRO-for-Phase-2-Berubicin-Trials.html
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities